Kestra Medical Technologies, Ltd. (NASDAQ:KMTS – Get Free Report) CFO Vaseem Mahboob sold 5,391 shares of the business’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $23.80, for a total transaction of $128,305.80. Following the completion of the sale, the chief financial officer owned 93,891 shares in the company, valued at approximately $2,234,605.80. The trade was a 5.43% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Vaseem Mahboob also recently made the following trade(s):
- On Friday, July 31st, Vaseem Mahboob sold 8,817 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $22.61, for a total value of $199,352.37.
- On Thursday, July 30th, Vaseem Mahboob sold 3,980 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $22.75, for a total value of $90,545.00.
Kestra Medical Technologies Price Performance
NASDAQ:KMTS opened at $23.99 on Tuesday. The business’s 50-day moving average is $22.62 and its 200 day moving average is $22.48. Kestra Medical Technologies, Ltd. has a 12 month low of $14.10 and a 12 month high of $30.00. The company has a market capitalization of $1.41 billion, a P/E ratio of -9.91 and a beta of 0.58. The company has a current ratio of 4.41, a quick ratio of 4.41 and a debt-to-equity ratio of 0.16.
Trending Headlines about Kestra Medical Technologies
Here are the key news stories impacting Kestra Medical Technologies this week:
- Neutral Sentiment: Multiple executives, including CFO Vaseem Mahboob and insiders Brian Daniel Webster, Traci S. Umberger, Alfred J. Ford Jr. and Timothy P. Moran, sold shares between July 30 and August 3. The transactions totaled approximately 103,000 shares and more than $2.3 million at prices near $22.60–$23.92. Each filing states that the sales were made to cover tax-withholding obligations tied to vested equity awards, rather than for discretionary investment purposes. SEC insider transaction filings
- Negative Sentiment: The breadth of the selling—including transactions by the CFO and several other insiders—could weigh on sentiment because it reduces management ownership and creates a perception of insider selling pressure. However, the relatively small percentage reductions in most positions and the disclosed tax-related purpose make the signal less bearish than open-market sales based on an expectation of weaker business performance.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of the company. California State Teachers Retirement System increased its position in Kestra Medical Technologies by 39.2% during the first quarter. California State Teachers Retirement System now owns 27,835 shares of the company’s stock valued at $555,000 after acquiring an additional 7,844 shares during the last quarter. The Manufacturers Life Insurance Company lifted its holdings in shares of Kestra Medical Technologies by 6.6% in the 1st quarter. The Manufacturers Life Insurance Company now owns 92,515 shares of the company’s stock worth $1,844,000 after acquiring an additional 5,731 shares during the last quarter. Quantinno Capital Management LP purchased a new position in shares of Kestra Medical Technologies during the 1st quarter worth about $431,000. Sei Investments Co. grew its holdings in Kestra Medical Technologies by 22.6% during the 1st quarter. Sei Investments Co. now owns 237,116 shares of the company’s stock valued at $4,726,000 after purchasing an additional 43,753 shares during the last quarter. Finally, Spartan Wealth Advisory Services LLC purchased a new stake in Kestra Medical Technologies in the 1st quarter worth about $603,000.
Wall Street Analysts Forecast Growth
Several research firms have commented on KMTS. Oppenheimer assumed coverage on shares of Kestra Medical Technologies in a research report on Tuesday, July 21st. They set a “market perform” rating for the company. BTIG Research upped their target price on shares of Kestra Medical Technologies from $30.00 to $32.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th. The Goldman Sachs Group lowered their price target on shares of Kestra Medical Technologies from $22.00 to $17.00 and set a “neutral” rating for the company in a report on Thursday, April 9th. Wolfe Research set a $30.00 price target on Kestra Medical Technologies in a research report on Wednesday, July 15th. Finally, Wall Street Zen downgraded Kestra Medical Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. Three analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Kestra Medical Technologies presently has an average rating of “Hold” and an average price target of $27.83.
Get Our Latest Report on Kestra Medical Technologies
About Kestra Medical Technologies
We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.
Read More
- Five stocks we like better than Kestra Medical Technologies
- SpaceX’s First Earnings Report Could Decide Whether Shorts or Bulls Have Control
- Why Rare Earth Processing Could Be the Real 2027 Opportunity
- The S&P 493 Are Staging a Comeback—This Value ETF Offers Broad Exposure
- TSMC Insiders Are Buying the Pullback—But Is the Signal as Bullish as It Looks?
Receive News & Ratings for Kestra Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kestra Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
